References
- Bailey DG, Spence JD, Munoz C, et al. (1991). Interaction of citrus juices with felodipine and nifedipine. Lancet 337:268–9.
- Cvetkovic M, Leake B, Fromm MF, et al. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–71.
- de Castro WV, Mertens-Talcott S, Derendorf H, et al. (2008). Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J Agric Food Chem 56:4840–5.
- Ducharme MP, Warbasse LH, Edwards DJ. (1995). Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 57:485–91.
- Fukuda K, Ohta T, Oshima Y, et al. (1997). Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 7:391–6.
- He K, Iyer KR, Hayes RN, et al. (1998). Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252–9.
- Humphreys WG, Obermeier MT, Chong S, et al. (2003). Oxidative activation of acylguanidine prodrugs: intestinal presystemic activation in rats limits absorption and can be inhibited by co-administration of ketoconazole. Xenobiotica 33:93–106.
- Kamath AV, Yao M, Zhang Y, et al. (2005). Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 94:233–9.
- Kenny JR, Grime K. (2006). Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. Xenobiotica 36:351–65.
- Kupferschmidt HH, Fattinger KE, Ha HR, et al. (1998). Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45:355–9.
- Kupferschmidt HH, Ha HR, Ziegler WH, et al. (1995). Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58:20–8.
- Lilja JJ, Kivistö KT, Backman JT, et al. (1998). Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 64:655–60.
- Matsuda Y, Konno Y, Hashimoto T, et al. (2015). Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats. Pharm Res 32:604–16.
- Mohri K, Uesawa Y. (2001). Effects of furanocoumarin derivatives in grapefruit juice on nifedipine pharmacokinetics in rats. Pharm Res 18:177–82.
- Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–6.
- Rioux N, Bellavance E, Bourg S, et al. (2013). Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. Biopharm Drug Dispos 34:396–401.
- Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23.
- Wang EJ, Casciano CN, Clement RP, et al. (2001). Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res 18:432–8.
- Yamaoka K, Tanigawara Y, Nakagawa T, et al. (1981). A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879–85.
- Zhang QY, Dunbar D, Ostrowska A, et al. (1999). Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804–9.
- Zhang Y, Hsieh Y, Izumi T, et al. (1998). Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 287:246–52.
- Zuber R, Anzenbacherová E, Anzenbacher P. (2002). Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189–98.